A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2018
At a glance
- Drugs BIIB-095 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Biogen
- 23 Aug 2018 Planned End Date changed from 8 Dec 2018 to 28 Jan 2019.
- 23 Aug 2018 Planned primary completion date changed from 8 Dec 2018 to 28 Jan 2019.
- 06 Apr 2018 Status changed from not yet recruiting to recruiting.